← Back to catalogue

IDG/Sanzay

FDA UDI

Class II (US FDA UDI)

by IDG/SANZAY Corporation

Identity

Trade Name
IDG/Sanzay FDA UDI
Generic Name
Activated partial thromboplastin time (APTT) IVD, reagent FDA UDI
Device Name
The IDG APTT-EA reagent is an in vitro diagnostic assay intended for use in determining activated partial thromboplastin time (APTT) and coagulation factor assays that are based on a modified APTT. FDA UDI
Model / Reference
1 FDA UDI
Description
The IDG APTT-EA reagent is an in vitro diagnostic assay intended for use in determining activated partial thromboplastin time (APTT) and coagulation factor assays that are based on a modified APTT. FDA UDI

Identifiers

Catalog Number
HC201 FDA UDI
Primary DI / UDI-DI
00850053916199 FDA UDI
510(k) Number
K022021 FDA UDI
FDA Product Code
GFO FDA UDI
GMDN Term
Activated partial thromboplastin time (APTT) IVD, reagent FDA UDI

Classification

Device Class
Class II FDA UDI
Regulation Number
864.7925 FDA UDI
Commercial Distribution
In Commercial Distribution FDA UDI

Clinical & Handling

Sterile

No

FDA UDI

Single Use

No

FDA UDI

Implantable

No

FDA UDI

Contains Latex

No

FDA UDI

Prescription Use

No

FDA UDI

Over-the-Counter

Yes

FDA UDI

Convenience Kit

No

FDA UDI

Combination Product

No

FDA UDI

HCT/P

No

FDA UDI

Premarket Exempt

No

FDA UDI

Lot / Batch Number

Yes

FDA UDI

Serial Number

No

FDA UDI

Expiration Date

Yes

FDA UDI

Manufacturing Date

No

FDA UDI

Category: Activated partial thromboplastin time (APTT) IVD, reagent

IDG/Sanzay by IDG/SANZAY Corporation — Class II — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS

Similar devices

Also classified as Activated partial thromboplastin time (APTT) IVD, reagent.

Cleared under the same submission

Authorization Coverage (1 country)

Regulatory Authorizations

United States Pending data

FDA UDI

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Sources (1)

  • FDA UDI f66d24df-6d63-492b-8407-b8e38d00a895 35 fields · synced May 30, 2026